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Cell lines -Permanent clonal MDCK II cell lines expressing HA epitope-tagged WT and mutant V2Rs were developed using the CaPO 4 method as described previously (7) . Briefly, 10µg of V2pcD-N-HA, pCMV4N-V2R-L292P, pCMV4N-V2R-R337X, or pCMV4N-V2R-∆V278 (individual cDNAs encoding HA epitope-tagged human wild type (WT) or mutant (L292P, R337X, and ∆V278) V2Rs, respectively) were each co-transfected with 2µg pRSVneo (cDNA encoding neomycin resistance) into MDCK II cells. Colonies were selected based on resistance to G418, a neomycin analog, and isolated as described previously (7) . G418-resistant colonies were screened for WT V2R expression by assaying binding of the radioligand [ 3 H]AVP.
V2R mutant-expressing cell lines were screened via immunofluorescence against the HA epitope, using either the mouse 12CA5 monoclonal antibody or the rat anti-HA monoclonal antibody. Parental and stably expressing WT V2R MDCK II cells were maintained in DMEM supplemented with 10% fetal calf serum, 100units/mL penicillin, and 100µg/mL streptomycin at 37°C, 5% CO 2 . Simian kidney fibroblast (COS M6) cells were maintained in supplemented DMEM + 20mM HEPES. The studies presented were obtained in the WT V2R clonal cell line #61, which expresses the HA epitope-tagged WT V2R at a density of 12.6 pmol specific Transient Expression Studies -COS M6 cells were seeded the day prior to transfection at a density of 3.5 x 10 5 (35mm dish), 2.0 x 10 6 (100mm dish), or 4.5 x 10 6 (150mm dish). On the day of transfection, cells were rinsed in PBS prior to incubation with a mixture containing 0.67, 4, or 9µg of plasmid DNA, respectively, with 500µg/mL DEAE-Dextran for 20 minutes at 37°C, 5% CO 2 . The DNA/DEAE-Dextran mixture was aspirated and replaced with fresh DMEM supplemented with 20mM HEPES and 100µM chloroquine and maintained at 37°C, 5% CO 2 for 2 hours. At this time, the medium was aspirated and the cells were subjected to a DMSO shock (10% DMSO in DMEM, 3 minutes at 37°C) before replacing with 10% serum-supplemented DMEM + 20mM HEPES prior to assessment 72 hours post transfection. (1mg/mL) on the apical or basolateral surface as described previously (6;7). MDCK II cells plated in Transwells were pretreated overnight with 10µM SR121463B to achieve pharmacological rescue, or not (control), prior to surface biotinylation. The cells were scraped into RIPA with protease inhibitors present, and the extracts were centrifuged at 100,000 x g. The supernatant (detergent-solubilized preparation) was incubated overnight at 4°C with streptavidinagarose. The streptavidin-agarose resin was washed and eluted as above (10) , and the eluate resolved by SDS-PAGE on 12% gels. The resolved proteins were transferred to PVDF as described previously, and the biotinylated, epitope-tagged V2R identified by Western blot analysis using mouse HA.11 monoclonal antibody against the HA epitope.
Digestion of V2R with endoglycosidases − Proteins were eluted from Protein A agarose (for Fig. 10 ) or from streptavidin agarose (data not shown) using a buffer consisting of 0.5% SDS and 1% beta-mercaptoethanol. (Fig. 1A) , although it also could be visualized at intracellular sites when cells were permeabilized with Triton X-100 ( We utilized cell surface biotinylation strategies in COS M6 cells to provide quantitative information regarding the delivery of mutant V2R to the surface following rescue with temperature or SR121463B, using WT V2R as a comparator, as shown in Fig.3 . For these calculations, we defined the amount of WT V2R on the surface as 100%; in our studies we observed that 38% of the total WT V2R expressed in COS M6 cells was on the surface in the absence of SR121463B. SR121463B treatment leads to rescue of the L292P V2R from 8.0% to 38.2.0% of WT V2R surface expression; the R337X V2R from 22.0% to 88.9% of WT V2R surface expression; and the ∆V278 V2R from 5.3% to 21.2% of WT V2R surface expression (Fig. 3) . Interestingly, of the receptor expressed at the surface following exposure to SR121463B, virtually all of the WT V2R, R337X V2R, and ∆V278 V2R was in the mature glycosylated form, whereas none of the L292P V2R was detected in the mature glycosylated form (data not shown).
For V2R expressed in COS M6 cells and exposed to 28°C culture, quantitatively less mutant V2R was expressed at the cell surface overall. Furthermore, in contrast to findings for rescue by SR121463B, only ~ 50% of the R337X and ∆V278 V2R that reaches the cell surface achieves the mature glycosylated form; none of the L292P V2R achieves the mature glycosylated form. These data suggest that occupancy of the R337X and ∆V278 V2R by SR121463B stabilizes a single or limited set of V2R conformations that successfully achieve mature glycosylation, whereas incubation of cells at 28°C, does not. In neither circumstance is L292P converted to the mature glycosylated form, which will be discussed in more detail below for V2R expressed in polarized MDCK II cells. (Fig. 4B, black bars) . Cells expressing the ∆V278 V2R were unresponsive to AVP following incubation at 28°C (Fig. 4B) , despite surface localization of this mutant receptor under these conditions (Fig. 2O) . Thus, although the ∆V278 V2R can be spatially rescued to an extent apparently comparable to the L292P or R337X V2R structures, this Xlinked NDI allele must also possess defective AVP binding, coupling and/or signaling properties (16) .
Differential Sensitivity of V2R Mutants to Facilitated
As might have been predicted, pharmacological rescue to the cell surface also restores AVP-mediated cAMP production for receptors that manifest functional rescue following incubation at 28°C. As shown in Fig. 5 , for example, V2R antagonist treatment of cells expressing the L292P V2R led to a significant restoration of AVP-dependent cAMP production, consistent with findings following culture at 28°C, demonstrating the ability of this mutant allele to function properly once at the cell surface.
Despite temperature and pharmacological rescue of the L292P and R337X mutant V2R alleles, these mutant V2Rs were incapable of achieving AVP-mediated cAMP production quantitatively comparable to wild type V2R (Figs. 4B and 5). AVP dose response curves for mutant receptors rescued by incubation at 28°C revealed that L292P V2R and R337X V2R display a rightward shift in their ability to elicit AVP-mediated cAMP production, as well as a reduced maximal AVP stimulation (Fig. 6 ). These findings explain our inability to detect To more rigorously document the localization of these mutant V2Rs following pharmacological rescue, the basolateral versus the apical surfaces of V2R-expressing MDCK II cells were biotinylated, and the relative quantity of basolateral versus apical signal was evaluated for each V2R structure, with or without prior treatment with SR121463B (Fig. 9) . As demonstrated in metabolic labeling studies (Fig. 7B) , the WT V2R is selectively targeted to the basolateral surface independent of SR121463B treatment (Fig. 9A, lanes 3 versus 4) .
Quantitatively, 79-82% of the WT V2R is expressed at this surface ± SR121463B.
Unlike the WT V2R, 0.1% of the mutant R337X (Fig. 9B, lane 7) and none of the L292P ( For the L292P V2R, pharmacological rescue also results in basolateral expression of a mature glycosylated form of the receptor (Fig. 9C, lane 12 ), but this represents only 9% of the total cellular L292P V2R content. Surprisingly, in the absence of SR121463B, the L292P V2R appears at the apical surface (Fig. 9C, lane 9) ; SR121463B treatment enriches this apical expression by 5% (from 17% of the total cellular L292P V2R in the absence of SR121463B treatment to 22% of the total cellular L292P V2R content following antagonist treatment; Fig.   9C , lane 10). This apically expressed L292P V2R represents the immature glycosylated form of the receptor, based on its relative migration (cf. Fig. 9C , lanes 9-10 and Fig. 10 , lanes 4-6) and its sensitivity to Endo H (data not shown).
Maturation of the N-glycosylated V2R can be evaluated by sensitivity to Endo H and PNGase F. On SDS-PAGE, WT V2Rs migrate at M r ~ 45-55 kDa and ~38-40 kDa (Fig. 10A) ; V2R oligomers also can be detected and migrate at M r ~ 100 kDa (16) . The 38-40 kDa lower M r form is sensitive to endoglycosidase H, an enzyme that cleaves the mannose-rich immature glycosylated forms of cell surface glycoproteins (21) , suggesting that this is a precursor of the WT V2R. In contrast, the higher M r WT V2R is sensitive to degradation by PNGase F, which cleaves all N-glycosylated moieties (21), but is insensitive to endoglycosidase H, suggesting that This is because the V2R is also O-glycosylated and these sites are resistant to the endoglycosidase H or PNGase F enzymes (22) .
The mutant L292P V2R and R337X V2R migrate at M r ~ 38-40 kDa and ~30 kDa, respectively, without temperature or pharmacological rescue. These M r forms correspond to the immature glycosylation forms of these two receptor structures, as evidenced by their sensitivity to both endoglycosidase H and PNGase F (Figs. 10B and C).
Discussion
Appropriate receptor localization constitutes an essential first step in permitting target cells to respond correctly to extracellular cues. Localization may also define, at least in part, selective interactions between receptors and effectors in surface microcompartments.
Mislocalization of receptors due to inherited mutations plays a significant role in the etiology of multiple disease states, as reviewed by Edwards et al. (23) . In the case of human alleles of the V2R (the model system evaluated in this study), more than 70% of the receptor coding mutations that lead to X-linked NDI are due to intracellular receptor accumulation (24) . V2R trapped inside cells are unresponsive to the physiological hormone, AVP, which does not readily cross the membrane surface. Retained mutant V2R cannot participate in coupling to adenylyl cyclase and subsequent cAMP production, and therefore cannot recruit pre-formed aquaporin 2 channels to the apical surface of renal epithelia (24) .
The present studies evaluating three clinically relevant mutant V2Rs, L292P, ∆V278, and R337X, document that these alleles encode mutant receptors that are trapped intracellularly. Our findings are the first to show that these alleles are temperature-sensitive, and can be rescued to the surface by incubation of mutant V2R-expressing COS M6 cells at reduced temperature (28°C). To our knowledge, these findings represent the first data identifying temperaturesensitive V2R mutants. Polytopic proteins that manifest temperature-sensitive protein folding defects have been described previously and include mutants of the lutropin/choriogonadotropin GPCR (25), the ∆F508 CFTR (26) and the N470D HERG potassium channel (13) . These folding defects give rise to abnormal proteins that are nonfunctional and/or result in retention within cytosolic compartments. Reduction in growth temperature is interpreted to foster proper protein folding, manifest as increased cell surface expression, as is the case for the V2R mutants examined here.
The present studies also demonstrate that X-linked NDI V2R mutants can be rescued to the surface pharmacologically, by binding of a membrane-permeant V2R antagonist (SR121463B), by analogy with other pharmacologically rescued alleles of the V2R (15). We know, however, that rescue to the surface is not necessarily sufficient to achieve V2R function, as exemplified by the ∆V278 V2R. This mutant allele does not couple to cAMP production following surface rescue, suggesting that this molecule has either deficient binding, coupling to G sα , or both (19). Even L292P V2R and R337X V2R, after rescue to the surface, do not manifest quantitatively similar cAMP stimulation responses as the WT V2R. Thus, the maximal stimulation of cAMP that these alleles can achieve is reduced compared to WT V2R, and the concentration-response curve for cAMP production in response to AVP is moved rightward, consistent with the interpretation that binding or coupling to G sα , or both, are still perturbed in the L292P and R337X V2R despite rescue at permissive temperatures.
As expected, the intracellularly trapped V2R mutants reflect immature glycosylated forms of the receptor, and are sensitive to digestion by endoglycosidase H. Moreover, basolateral delivery of pharmacologically rescued L292P V2R and R337X V2R occurs principally for the mature glycosylated form of the receptor. Therefore, it appears that rescue (and presumably normal trafficking) to the appropriate surface of polarized renal epithelial cells involves a conformation of the receptor that is capable of migration through the Golgi network to achieve mature N-linked glycosylation as well as delivery to basolaterally targeted vesicles.
However, this interpretation is not meant to imply that receptor glycosylation is an absolute requirement for basolateral delivery, since mutations of the WT V2R that eliminate Nglycosylation of the receptor do not alter basolateral targeting (27). These findings are similar to those for other GPCRs, such as the α 2A -adrenergic receptor; mutations that eliminate N-linked glycosylation of the receptor do not perturb direct basolateral delivery of the receptor (7). We further substantiated the lack of a requirement for N-linked glycosylation of the V2R for direct basolateral delivery by demonstrating that overnight incubation with 5µg/mL tunicamycin resulted in the elimination of N-linked glycosylation of nascent V2R, but these V2Rs (Mr ~ 40 kDa) remained correctly targeted to the basolateral surface of polarized MDCK II cells (data not shown).
In light of our finding that appropriate delivery to the basolateral surface involves a conformation of the V2R that is also capable of mature glycosylation and migration through the Golgi to basolaterally targeted vesicles in the trans-Golgi network, we were surprised to observe that a fraction of the immature glycosylated form of the L292P V2R is delivered to the cell surface in the absence of temperature-sensitive or pharmacological rescue, but that this delivery is to the "wrong", i.e. apical, surface of polarized MDCK II cells (Fig. 9C) . In fact, occasionally we could detect this apical L292P V2R on the apical surface in confocal images (cf. Fig. 8F and I). We do not know by what vesicular pathway the immature glycosylated form of the L292P V2R reaches the apical surface; however, this apically-delivered L292P V2R remains sensitive to degradation by Endo H, confirming that it represents an immature glycosylated form of the receptor. Notably, the mature, glycosylated form of the L292P V2R is found only on the basolateral surface after pharmacological rescue. These data are consistent with binding of SR121463B to intracellularly accumulated L292P V2R, resulting in stabilization of a fraction of the V2R in a conformation capable of attaining both mature glycosylation and correct localization to the appropriate (i.e., basolateral) surface. We note that it is only for the L292P V2R that we see significant escape to the apical surface. This may be because this mutation is predicted to occur within the bilayer region of the V2R, and may lead to substantial misfolding of the receptor, of which only a small fraction is successfully refolded in the presence of SR121463B. In contrast, R337X V2R represents a structure with only a truncation in the C terminal tail, and misfolding may not be as extreme as for the L292P V2R. Indeed, we always observe quantitatively more rescue of the mature form of R337X than L292P V2R to the basolateral surface when comparing total cell extracts in the absence versus the presence of SR121463B, especially following the V2R antagonist treatment.
Several mutants, such as ∆F508CFTR in cystic fibrosis (26) and the N470D HERG potassium channel in congenital long QT syndrome (13) , have been demonstrated to be defective in protein trafficking but are capable of wild type-like function when rescued to the cell surface.
We interpret the rescue of cell surface expression and AVP-mediated receptor function of the Immunostaining to visualize receptors found both at the cell surface and within intracellular compartments was performed with rat anti-HA antibody in the presence of 0.2% Triton X-100 detergent to permeabilize cells (panels E-H). Labeling with the rat anti-HA primary monoclonal antibody was detected by an Alexafluor488-conjugated goat anti-rat IgG secondary antibody. 
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